Urinary [TIMP-2] × [IGFBP7] and serum procalcitonin to predict and assess the risk for short-term outcomes in septic and non-septic critically ill patients

Annals of Intensive Care

Table 3 Risk assessment for primary and secondary outcomes in the entire population and in septic and non-septic subgroups

Variables	Analysis cohort			Sepsis			Non-sepsis
Variables	OR	95% CI	p-value	OR	95% CI	p-value	OR	95% CI	p-value
Primary outcome
AKI within 48 h
[TIMP-2] × [IGFBP7] > 0.3	3.93^a	2.14–7.20	< 0.001	5.92^a	2.53–13.82	< 0.001	3.27^a	1.53–6.97	< 0.001
PCT > 0.5	3.67^a	2.17–6.19	< 0.001	2.74^a	0.87–8.57	0.083	4.85^a	2.37–9.94	< 0.001
Single-marker positivity	4.08	1.90–8.76	< 0.001	2.27	0.45–11.23	0.316	4.93	2.05–11.82	< 0.001
Double-marker positivity	26.41	12.32–56.62	< 0.001	19.5	4.20–90.44	< 0.001	25.11	9.58–65.79	< 0.001
Secondary outcomes
AKD at 7 days
Single-marker positivity	4.73	1.04–21.60	0.045	2.28	0.26–20.02	0.15	3.24	0.65–16.20	0.151
Double-marker positivity	15.92	3.67–68.97	0.001	4.57	0.48–36.25	0.15	15.36	3.21–73.57	0.001
Mortality within 7 days
Single-marker positivity	1.16	0.51–2.65	0.724	0.86	0.77–2.75	0.494	1.59	0.63–4.05	0.329
Double-marker positivity	2.75	1.34–5.65	0.006	4.1	1.41–11.78	0.001	2.01	0.75–5.40	0.166

A single-marker positivity was defined by the presence of [TIMP-2] × [IGFBP7] above the cut-off of 0.3 or PCT above the cut-off of 0.5; the double-marker positivity was defined by the presence of [TIMP-2] × [IGFBP7] measurements above 0.3 and the concomitant presence of PCT levels above 0.5
[TIMP-2] × [IGFBP7] tissue inhibitor metalloproteinase-2 and insulin-growth factor binding protein 7 product, PCT procalcitonin
^a Odds ratios (OR) were adjusted for Sequential Organ Failure Assessment (SOFA) and estimated glomerular filtration rate (eGFR) at the time of admission